Physician profile
Charleen Singh
NPI 1467890327
$120,526.37
in general payments reported to CMS, 2019-2025
5 companies · $46K in 2025
The $46K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $7,783 · 2023: $1,200 · 2024: $53K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $56K · Travel and Lodging: $33K · Consulting Fee: $9,403 · Food and Beverage: $1,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,250.00 |
| Travel and Lodging | $32,673.18 |
| Consulting Fee | $9,403.03 |
| Food and Beverage | $1,657.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Molnlycke Health Care US, LLC | $102,513.40 | 2021-2025 | Mepilex Border Sacrum, Tortoise Turning & Positioning System, Mepilex Border |
| Coloplast Corp | $17,612.15 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $153.99 | 2025 | Uzedy, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $121.84 | 2024 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charleen Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.